Free Trial
NASDAQ:MDXH

MDxHealth (MDXH) Stock Price, News & Analysis

MDxHealth logo
$1.48 -0.02 (-1.67%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MDxHealth Stock (NASDAQ:MDXH)

Key Stats

Today's Range
$1.47
$1.55
50-Day Range
$1.42
$2.35
52-Week Range
$1.35
$3.50
Volume
89,234 shs
Average Volume
86,100 shs
Market Capitalization
$69.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Buy

Company Overview

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Remove Ads

MDxHealth Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

MDXH MarketRank™: 

MDxHealth scored higher than 55% of companies evaluated by MarketBeat, and ranked 572nd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MDxHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MDxHealth has received no research coverage in the past 90 days.

  • Read more about MDxHealth's stock forecast and price target.
  • Earnings Growth

    Earnings for MDxHealth are expected to grow in the coming year, from ($1.15) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MDxHealth is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MDxHealth is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MDxHealth has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MDxHealth's valuation and earnings.
  • Percentage of Shares Shorted

    0.15% of the float of MDxHealth has been sold short.
  • Short Interest Ratio / Days to Cover

    MDxHealth has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MDxHealth has recently increased by 133.83%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MDxHealth does not currently pay a dividend.

  • Dividend Growth

    MDxHealth does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.15% of the float of MDxHealth has been sold short.
  • Short Interest Ratio / Days to Cover

    MDxHealth has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MDxHealth has recently increased by 133.83%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MDxHealth has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for MDxHealth this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    2 people have added MDxHealth to their MarketBeat watchlist in the last 30 days.
Receive MDXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MDxHealth and its competitors with MarketBeat's FREE daily newsletter.

MDXH Stock News Headlines

DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.
Piper Sandler Sticks to Its Buy Rating for MDxHealth (MDXH)
MDxHealth sees FY25 revenue $108M-$110M, consensus $98.93M
See More Headlines

MDXH Stock Analysis - Frequently Asked Questions

MDxHealth's stock was trading at $2.37 at the beginning of the year. Since then, MDXH stock has decreased by 37.1% and is now trading at $1.49.
View the best growth stocks for 2025 here
.

MDxHealth SA (NASDAQ:MDXH) announced its quarterly earnings data on Wednesday, February, 26th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.07. The company had revenue of $24.74 million for the quarter, compared to analyst estimates of $22.67 million. MDxHealth had a negative trailing twelve-month return on equity of 1,077.84% and a negative net margin of 49.52%.

MDxHealth shares reverse split before market open on Friday, December 29th 2023. The 1-10 reverse split was announced on Monday, October 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

MDxHealth (MDXH) raised $45 million in an IPO on Thursday, November 4th 2021. The company issued 3,750,000 shares at a price of $12.00 per share.

Top institutional shareholders of MDxHealth include Bleichroeder LP (15.60%), AWM Investment Company Inc. (9.98%), Samjo Management LLC (3.86%) and Perkins Capital Management Inc. (2.08%).
View institutional ownership trends
.

Shares of MDXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MDxHealth investors own include Cognition Therapeutics (CGTX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), PHX Minerals (PHX), PayPal (PYPL), Arcadia Biosciences (RKDA) and Alimera Sciences (ALIM).

Company Calendar

Last Earnings
2/26/2025
Today
3/14/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:MDXH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.50
High Stock Price Target
$7.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+336.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-43,100,000.00
Pretax Margin
-49.12%

Debt

Sales & Book Value

Annual Sales
$90.05 million
Price / Cash Flow
N/A
Book Value
$4.62 per share
Price / Book
0.32

Miscellaneous

Free Float
46,484,000
Market Cap
$70.46 million
Optionable
Not Optionable
Beta
1.37
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:MDXH) was last updated on 3/14/2025 by MarketBeat.com Staff
From Our Partners